Factors associated with non use of adjuvant trastuzumab in older patients with HER2+breast cancer.

被引：0
|
作者：
Luis, Ines Vaz
Lin, Nancy U.
Keating, Nancy Lynn
Barry, William Thomas
Lii, Joyce
Burstein, Harold J.
Winer, Eric P.
Freedman, Rachel A.
机构：
[1] Dana Farber Canc Inst, Boston, MA 02115 USA
[2] Harvard Med Sch, Boston, MA 02115 USA
[3] Brigham & Womens Hosp, Div Pharmacoepidemiol & Pharmacoecon, 75 Francis St, Boston, MA 02115 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2016年 / 34卷 / 15期
关键词：
D O I：
10.1200/JCO.2016.34.15_suppl.601
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
601
引用
收藏
页数：2
相关论文
共 50 条
  • [21] A Review and Meta-analysis on Trastuzumab Resistance in Patients with HER2+Breast Cancer
    Holzbach, Alexandre
    Cima, Bernardo Perin
    Staffen, Mari Dalva
    Lindenau, Juliana Dal-Ri
    Muniz, Yara Costa Netto
    [J]. MINI-REVIEWS IN MEDICINAL CHEMISTRY, 2023, 23 (11) : 1222 - 1236
  • [22] Survival of patients with advanced HER2+breast cancer. Analysis of a cancer center database
    Sanchez, Cesar
    Dominguez, Francisco
    Galindo, Hector
    Camus, Mauricio
    Oddo, David
    Villarroel, Alejandra
    Razmilic, Dravna
    Elena Navarro, Maria
    Perez-Sepulveda, Alejandra
    Medina, Lidia
    Lopez, Valeska
    Aceved, Francisco
    [J]. REVISTA MEDICA DE CHILE, 2018, 146 (10) : 1095 - 1101
  • [23] Factors associated with the use of adjuvant neratinib in stage I-III HER2-positive breast cancer.
    Stoen, Ericson
    Kagihara, Jodi
    Kabes, Pater
    Fisher, Christine M.
    Diamond, Jennifer Robison
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [24] Relationship of healthcare costs and disease progression in patients with HER2+breast cancer.
    Goertz, Hans-Peter
    Sheinson, Daniel
    Wu, Ning
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [25] Transcriptome and chromatin landscape changes associated with trastuzumab resistance in HER2+breast cancer cells
    Murad, Rabi
    Avanes, Arabo
    Ma, Xinyi
    Geng, Shuhui
    Mortazavi, Ali
    Momand, Jamil
    [J]. GENE, 2021, 799
  • [26] Genomic alterations associated with HER2+breast cancer risk and clinical outcome in response to trastuzumab
    Singla, Heena
    Kaur, Raman Preet
    Shafi, Gowhar
    Vashistha, Rajesh
    Banipal, Raja Paramjeet Singh
    Kumar, Vinod
    Munshi, Anjana
    [J]. MOLECULAR BIOLOGY REPORTS, 2019, 46 (01) : 823 - 831
  • [27] Comparative toxicity and effectiveness of trastuzumab combined with anthracycline versus platinum chemotherapy regimens for adjuvant therapy of HER2+breast cancer in older women
    Reeder-Hayes, K. E.
    Meyer, A. M.
    Hinton, S. P.
    Ke, M.
    Carey, L. A.
    Dusetzina, S. B.
    [J]. CANCER RESEARCH, 2017, 77
  • [28] Use of trastuzumab associated with cisplatin and vinorelbine followed by docetaxel as a neoadjuvant regimen for patients with HER2-positive breast cancer.
    Carillio, G.
    Aiello, R.
    Mazzola, A.
    Ali', M.
    Scandurra, G.
    Talbi, E.
    Chiarenza, M.
    Fallica, G.
    Caruso, F.
    Caruso, M.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [29] Effect of cyclin E overexpression on resistance to trastuzumab and phosphorylation of SMAD3 in HER2+breast cancer.
    Kandagatla, Pridvi
    Decker, Joseph
    Wan, Lei
    Bernstein, Regan
    Shea, Lonnie
    Jeruss, Jacqueline Sara
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [30] Safety of adjuvant trastuzumab (T) in elderly patients with breast cancer.
    Militello, L.
    Carli, P.
    Spazzapan, S.
    Lestuzzi, C.
    Miolo, G.
    Scalone, S.
    Veronesi, A.
    Crivellari, D.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (27)
12345